SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001851734-23-000037
Filing Date
2023-02-07
Accepted
2023-02-07 16:29:22
Documents
15
Period of Report
2023-02-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K vtgn20230207_8k.htm   iXBRL 8-K 25014
2 EXHIBIT 99.1 ex_472641.htm EX-99.1 137384
7 vistagen.jpg GRAPHIC 4171
  Complete submission text file 0001851734-23-000037.txt   315370

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vtgn-20230207.xsd EX-101.SCH 3600
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vtgn-20230207_def.xml EX-101.DEF 11531
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE vtgn-20230207_lab.xml EX-101.LAB 15413
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vtgn-20230207_pre.xml EX-101.PRE 11687
9 EXTRACTED XBRL INSTANCE DOCUMENT vtgn20230207_8k_htm.xml XML 2594
Mailing Address 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 650-577-3600
VistaGen Therapeutics, Inc. (Filer) CIK: 0001411685 (see all company filings)

IRS No.: 205093315 | State of Incorp.: NV | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-37761 | Film No.: 23595444
SIC: 2834 Pharmaceutical Preparations